 "Suven grants Taro Pharma licence to market Malathion lotion in North America")
Hyderabad-based bio-pharmaceutical and contract research and manufacturing company, Suven Life Sciences, has announced the grant of exclusive licence and right to distribute and market its Malathion lotion in the USA, Canada and Mexico, to Taro Pharmaceuticals North America, a subsidiary of Taro Pharma Industries Ltd.
The Malathion lotion is indicated for patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair.
In consideration for the exclusive licence, Taro will pay Suven a royalty and the arrangement is effective until April 2028, Suven stated in a release to stock exchanges today.
Suven was trading at Rs 74.70 on BSE, up Rs 1.45 or 1.98 per cent over the previous day's close of Rs 73.25.